Docetaxel trihydrate NEW
| Price | $46 |
| Package | 100mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: Docetaxel trihydrate | CAS No.: 148408-66-6 |
| Purity: 99.84% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | Docetaxel trihydrate |
| Description | Docetaxel trihydrate (RP-56976 Trihydrate) is an antineoplastic agent that has a unique mechanism of action as an inhibitor of cellular mitosis and that currently plays a central role in the therapy of many solid tumor including breast and lung cancer. Therapy with docetaxel has been associated with a low rate of serum enzyme elevations and rarely to instances of acute hepatic necrosis generally due to severe hypersensitivity reactions or sepsis. |
| Cell Research | 2000 cells in 180 μL of medium are seeded in a 96-well plate, and 20 μL of drug solution is simultaneously added in triplicate to each well. The plate is incubated for 3 days at 37°C in a humidified atmosphere of 5% CO2. On day 3, 25 μL of MTT reagent is added to each well. After 4 h of incubation, the medium is removed by aspiration. 0.2 mL of dimethylsulphoxide (DMSO) is added to each well and thoroughly mixed by using a mechanical plate mixer to dissolve the resulting MTT-formazan crystals. Absorbance at 540 nm (OD) is measured by a reader. (Only for Reference) |
| In vitro | Administering 33 mg/kg of Docetaxel every four days for three doses resulted in a 19.3-day growth delay in M2OL2 colorectal cancer xenografts. Docetaxel exhibited potent antitumor activity in MX-1, SK-MEL-2, LX-1, and OVCAR-3 xenograft models. Biweekly administration of Docetaxel over 14 days suppressed fibroblast growth factor 2-mediated angiogenesis with an IC50 of 5.4 mg/kg. A dose of 10 mg/kg Docetaxel completely inhibited angiogenesis in mice. |
| In vivo | Docetaxel inhibits the clonogenic survival of various human cancer cell lines including Hs746T (stomach), AGS (stomach), HeLa (cervical), CaSki (cervical), BxPC3 (pancreatic), and Capan-1 (pancreatic) with IC50 values of 1 nM for the stomach, and 0.3 nM for the others, respectively. Additionally, Docetaxel suppresses the chemotaxis of human umbilical vein endothelial cells stimulated by angiogenic factors, thymidine phosphorylase, or VEGF, with an IC50 of 10 pM. Moreover, Docetaxel induces the expression of Prostaglandin H Synthase-2 (PGHS-2) in human monocytes without affecting its expression in RAW 264.7 mouse macrophages. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 100 mg/mL (116.02 mM), Sonication is recommended. 10% DMSO+90% Saline : < 10 mg/mL (11.6 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. DMSO : 250 mg/mL (290.04 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (11.6 mM), Solution. |
| Keywords | Tubulin β-1 chain | RP56976 (NSC 628503) | RP-56976 | RP56976 | RP 56976 | MicrotubuleAssociated | Microtubule/Tubulin | Microtubule Associated | Inhibitor | inhibit | Docetaxel trihydrate | Docetaxel | Bcl-2 | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Anti-Tumor Natural Product Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Alkaloid Natural Product Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Microtubule-Targeted Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP2Y
|
Shaanxi Xianhe Biotech Co., Ltd
|
2026-06-15 | ||
|
VIP3Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-06-12 | ||
| $46.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
| $46.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
| $5.00 |
Wuhan JiyunZen Tech Co., Ltd.
|
2026-04-10 | ||
| $15.00 |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-13 | ||
| $1.00 |
VIP8Y
|
Career Henan Chemical Co
|
2019-07-06 | |
| $46.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-04-28 | |
| $15.00 |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-09 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY